Skip to main content
2024 Guide to Patient Support Services

Spectrum Pharmaceuticals

2024 PSS Guide

Spectrum Pharmaceutical’s Access4Me

Spectrum Pharmaceuticals offers the Access4Me program to provide access and reimbursement support to patients who have been prescribed Rolvedon (Table).

Rolvedon Copay Assistance Program

The Rolvedon Copay Assistance Program may reduce out-of-pocket costs for patients with commercial insurance to as little as $0, up to a maximum annual benefit of $15,000 per 12-month enrollment period.

Rolvedon Patient Assistance Program

Patients who are uninsured or underinsured may be eligible to receive Rolvedon at no cost through the Patient Assistance Program.

First-Cycle Patient Support Program

New patients can receive their first-cycle dose of Rolvedon free of charge. When enrolling the patient, simply check First-Cycle Patient Support on the enrollment form. Access4Me will conduct the benefits investigation, communicate the results to your office, and confirm patient eligibility for the free dose. This program is limited to one free dose per patient.

To enroll your patient in the Access4Me program, visit Access4Me.

TABLE Spectrum Oncology Supportive Drug

Patient support program

Rolvedon (eflapegrastim-xnst) injection
To decrease the incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with clinically significant incidence of febrile neutropenia
Patient support program